Summaries for patients. Influenza vaccination or antiviral treatment for healthy working adults: an economic analysis.
D000081:Acetamides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003198:Computer Simulation; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006146:Guanidines; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*; D008875:Middle Aged; D053139:Oseltamivir; D011714:Pyrans; D012299:Rimantadine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D012794:Sialic Acids / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014611:Vaccination / Q000191:economics*; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D006146:Guanidines; D007252:Influenza Vaccines; D011714:Pyrans; D012794:Sialic Acids; D012299:Rimantadine; D053139:Oseltamivir; D053243:Zanamivir